News for Hikma Pharmaceuticals PLC (HIK.L)

PR NewswireCOLUMBUS, Ohio, June 28, 2025 Next phase builds on 34+ years of serving the needs of US patients and healthcare providersCOLUMBUS, Ohio, June 28

Summary Hikma Pharmaceuticals PLC (HKMPY) and Bio-Thera Solutions have announced the U.S. FDA approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar

PR NewswireGUANGZHOU, China and LONDON, May 27, 2025 GUANGZHOU, China and LONDON, May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a comm

PR NewswireGUANGZHOU, China and LONDON, May 27, 2025 GUANGZHOU, China and LONDON, May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a comm

Summary Hikma Pharmaceuticals PLC (HKMPY), a leading multinational pharmaceutical company, announced on April 17, 2025, that it has acquired the FDA-approved Ab

PR NewswireLONDON, April 17, 2025 LONDON, April 17, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today

Jazz Pharmaceuticals JAZZ.O said on Tuesday that it had agreed to a settlement of $145 million to resolve a series of antitrust lawsuits related to its

Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada LONDON and

**media[571897,571898]**

Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada

Fourth Quarter 2024 Total Revenues of $194.7 million; Full Year 2024 Total Revenues of $1.04 billionFourth Quarter 2024 Net Loss of $31.3 million, decrease in N

Release Date: February 26, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Hikma Pharma

Feb 26, 2025 / 09:00AM GMTRiad Mishlawi - Hikma Pharmaceuticals PLC - Chief Executive Officer, Executive Director Thank you for joining our 2024 full-year resul

U.K. stocks lower at close of trade; Investing.com United Kingdom 100 down 1.23%

U.K. stocks higher at close of trade; Investing.com United Kingdom 100 up 1.38%

The Cancer Cachexia Market Size sector reached a market value of USD 2.02 Billion in 2019. Future projections show a bright outlook, with a Compound Annual Growth Rate (CAGR) of 5% from 2019 to 2032…

Sickle Cell Disease Market Size Was Valued at USD 2.40 Billion in 2023, and is Projected to Reach USD 12.38 Billion by 2032, Growing at a CAGR of 20.00%...

The need for antiemetic drugs, which help prevent or relieve nausea and vomiting, is growing for several reasons. A key factor is the rising incidence of...

Huntingtons disease treatment industry is projected to witness a CAGR of 20.8% during the period 2024-2032. This growth can be attributed to the limited...